

1 **Effectiveness of vaccination against SARS-CoV-2 infection and**  
2 **Covid-19 hospitalization among Finnish elderly and chronically**  
3 **ill – An interim analysis of a nationwide cohort study**

4

5

6 Ulrike Baum<sup>1\*</sup>, Eero Poukka<sup>1\*</sup>, Arto A. Palmu<sup>2</sup>, Heini Salo<sup>1</sup>, Toni O. Lehtonen<sup>1</sup>, Tuija Leino<sup>1</sup>

7

8 1. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish  
9 Institute for Health and Welfare (THL), Helsinki, Finland

10 2. Population Health Unit, Department of Public Health and Welfare, Finnish Institute for  
11 Health and Welfare (THL), Tampere, Finland

12

13 \* Both authors contributed equally

14

15 Abstract: 250 words (max 250 words)

16 Manuscript: 2688 words (max 3000 words)

17 Keywords: SARS-CoV-2, Covid-19, vaccine effectiveness, elderly, chronically ill (max 5)

18 Running title: Effectiveness of Covid-19 vaccines (36 max 40 characters)

19 40-word summary: This register-based cohort study demonstrates that Covid-19 vaccines protect  
20 against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically  
21 ill. Vaccine effectiveness against hospitalization was moderate after 1 dose and increased to  $\geq 90\%$   
22 after 2 doses.

23 **Abstract**

24 *Background*

25 In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the  
26 vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill  
27 was prioritized and the interval between doses set to 12 weeks. The objective of this interim  
28 analysis was to evaluate first and second dose vaccine effectiveness (VE) in a real-world setting.

29

30 *Methods*

31 During the first 5 months of the campaign, a register-based cohort study was conducted in the  
32 Finnish elderly aged 70+ years and those aged 16–69 years with medical conditions predisposing  
33 to severe Covid-19 (chronically ill). Using Cox regression, VE against SARS-CoV-2 infection and  
34 Covid-19 hospitalization was estimated comparing the hazard in the vaccinated with that in the  
35 unvaccinated.

36

37 *Results*

38 The cohorts included 901092 elderly (89% vaccinated) and 774526 chronically ill (69% vaccinated)  
39 individuals. Three weeks after the first dose, mRNA VE against infection was 45% (95% confidence  
40 interval, 36–53%) and 40% (26–51%) in elderly and chronically ill; mRNA VE against hospitalization  
41 was 63% (49–74%) and 82% (56–93%). In chronically ill, AdV VE was 42% (32–50) and 62% (42–  
42 75%) against infection and hospitalization, respectively. One week after the second dose, mRNA  
43 VE against infection was 75% (65–82%) and 77% (65–85%) in elderly and chronically ill; mRNA VE  
44 against hospitalization was 93% (70–98%) and 90% (29–99%).

45

46 *Conclusions*

47 Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalization. A single dose  
48 provides moderate protection in elderly and chronically ill, although 2 doses are clearly superior.

49

50

51 **Introduction**

52 The global burden of the ongoing Covid-19 pandemic caused by the severe acute respiratory  
53 syndrome coronavirus 2 (SARS-CoV-2) has been immense. Finland, a Nordic country with 5.5  
54 million inhabitants, has been less affected than the rest of Europe [1]. As of May 24, 2021, there  
55 have been roughly 90 000 confirmed Covid-19 cases and 942 Covid-19-associated deaths in the  
56 Finnish population [2].

57

58 In late 2020 the European Medicines Agency authorized the first Covid-19 vaccines for use in the  
59 European Union [3]. Finland started its vaccination campaign promptly after, on December 27,  
60 prioritizing healthcare workers treating Covid-19 patients as well as residents and healthcare  
61 workers of long-term care facilities [4]. Thereafter, the elderly aged 70+ years and individuals aged  
62 16+ years with (highly) predisposing medical conditions for severe Covid-19 were vaccinated [4].  
63 Due to vaccine shortage, Finland decided to postpone the second dose until 12 weeks after the  
64 first, similarly as in the United Kingdom (UK) [5], to provide more people with at least 1 dose as  
65 early as possible. Therefore, most of the elderly and chronically ill were vaccinated only once in  
66 the first quarter of 2021 [6]. By May 24, 2 messenger ribonucleic acid (mRNA) vaccines (by  
67 BioNTech/Pfizer and Moderna) and 2 adenovirus vector (AdV) vaccines (by Oxford/AstraZeneca  
68 and Janssen) have been approved by the European Medicines Agency [7] but only the first 3 have  
69 so far been used in Finland.

70

71 The first cohort studies assessing the effectiveness of Covid-19 vaccines were published in early  
72 2021. The vaccine effectiveness (VE) estimates for 2 doses from BioNTech/Pfizer varied between  
73 86% in healthcare workers and 92% in nationwide settings and, thus, were close to the vaccine  
74 efficacy measured in randomized controlled trials [8,9]. However, VE in the elderly and  
75 immunocompromised individuals has been suspected to be lower [10].

76

77 The aim of this observational study was to evaluate the interim effectiveness of Covid-19 vaccines  
78 in 2 cohorts, i.e. the elderly and the chronically ill, during the first 5 months of the vaccination  
79 campaign in Finland. As the administration of the second dose has been postponed, we focus  
80 especially on how the VE is sustained after the first dose.

81

82

### 83 **Methods**

84 To estimate effectiveness of Covid-19 vaccines in the elderly and the chronically ill in Finland, we  
85 conducted a cohort study based on data from 8 national registers linked using the unique Finnish  
86 personal identity code. The study follow-up begun with the first Covid-19 vaccinations in Finland  
87 (December 27, 2020) and ended on May 24, 2021. The 2 population-based study cohorts were the  
88 Finnish elderly aged 70+ years and the chronically ill aged 16–69 years at the beginning of the  
89 study. All study subjects were permanent residents and registered in the Population Information  
90 System, which provided information on each individual's date of birth and death (if applicable),  
91 sex and municipality of residence.

92

93 The cohort of the chronically ill was formed by individuals identified to be at increased risk of  
94 severe Covid-19 due to certain medical conditions. These conditions included active cancer  
95 treatment, organ or stem cell transplant, severe disorders of the immune system, severe chronic  
96 renal, liver or pulmonary disease, type 1 and type 2 diabetes, Down syndrome, severe heart  
97 disease, neurological illness or condition affecting breathing, immunosuppressive drug therapy for  
98 autoimmune disease, adrenal gland disorders, sleep apnea and psychotic disorders  
99 (Supplementary Table 1).

100

101 Distinguishing between predisposing and highly predisposing conditions (Supplementary Table 1),  
102 presence of the aforementioned medical conditions was determined in both cohorts using the  
103 diagnostic data in the Care Register for Health Care and the Register of Primary Health Care Visits  
104 since 2015 as well as the data in the Special Reimbursement Register and Prescription Centre  
105 database maintained by the Social Insurance Institution. The Special Reimbursement Register  
106 allowed the identification of all individuals entitled, at least until January 1, 2020, to a special  
107 reimbursement for medical expenses, indicating that the entitled individual met explicit criteria for  
108 selected medical conditions (Supplementary Table 1). The Prescription Centre database was used  
109 to identify all individuals using selected medications of interest (Supplementary Table 1).

110

111 The outcomes of interest were SARS-CoV-2 infection, laboratory-confirmed through polymerase  
112 chain reaction or antigen test as registered in the National Infectious Diseases Register, and Covid-  
113 19 hospitalization, recorded in the Care Register for Health Care, timely associated with a  
114 confirmed SARS-CoV-2 infection. Covid-19 hospitalization was defined as any inpatient hospital  
115 admission with Covid-19 (International Classification of Diseases, tenth revision, codes: U07.1,  
116 U07.2), acute respiratory tract infections (J00–J22, J46) or severe complications of lower

117 respiratory tract infections (J80–84, J85.1, J86) as primary or secondary diagnosis. Hospital  
118 admissions and SARS-CoV-2 infections were timely associated if the infection was confirmed up to  
119 14 days before or 7 days after the admission. Individuals with a confirmed SARS-CoV-2 infection  
120 prior to the study follow-up were excluded from the cohorts.

121

122 The exposure of interest was vaccination against Covid-19 with at least 1 dose of any vaccine,  
123 exactly 1 or 2 doses of mRNA vaccine, or exactly 1 or 2 doses of AdV vaccine (chronically ill only).  
124 The vaccine and date of vaccination were extracted from the National Vaccination Register. The  
125 time since vaccination with the first dose was split into the intervals 0–6 days since vaccination  
126 (DSV), 7–13 DSV, 14–20 DSV, 21–27 DSV, 28–34 DSV, 35–41 DSV and 42+ DSV. The time since  
127 vaccination with the second dose was split into the intervals 0–6 DSV and 7+ DSV.

128

129 Each study subject was considered to be at risk of the outcome of interest (confirmed SARS-CoV-2  
130 infection or Covid-19 hospitalization) from the beginning of the study until the first occurrence of  
131 any of the following events: outcome of interest, death, end of study, or day 14 after confirmed  
132 SARS-CoV-2 infection (if the outcome of interest was Covid-19 hospitalization). Using Cox  
133 regression with time in study as the underlying time scale, we compared the hazard of confirmed  
134 SARS-CoV-2 infection or Covid-19 hospitalization in vaccinated study subjects with the hazard in  
135 the unvaccinated. The effect measure of interest was VE, quantified as 1 minus the hazard ratio  
136 adjusted for age group (chronically ill: 16–38, 39–51, 52–59, 60–64, 65–69 years (age distribution  
137 quintiles); elderly: 70–74, 75–79, 80–89, 90+ years), sex, presence of medical conditions  
138 predisposing to severe Covid-19 (Supplementary Tables 1, 2 and 3), residence in the most affected  
139 hospital district Helsinki-Uusimaa (1.7 million inhabitants), and residence in long-term care (elderly  
140 only).

141

142 All analyses were performed in R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).

143

144

## 145 **Results**

146 The study cohorts of the elderly and the chronically ill included 901 092 and 774 526 individuals,  
147 respectively, of which 89% and 69% were vaccinated at least once against Covid-19 during the  
148 study follow-up. More than 90% of the vaccinated elderly had received mRNA vaccine, while  
149 among the chronically ill 2 thirds of the vaccinees had received mRNA vaccine; the rest had  
150 received AdV vaccine from Oxford/AstraZeneca (Figure 1). Only a small proportion was vaccinated  
151 twice (Figure 1). In the elderly, the vaccination coverage was similar across age groups, sex, and  
152 hospital districts (Supplementary Table 2). In the chronically ill, the vaccination coverage increased  
153 with age (Supplementary Table 3).

154

155 In total, there were 2265 cases of confirmed SARS-CoV-2 infection and 466 cases of Covid-19  
156 hospitalization among the elderly and 5929 cases of confirmed infection and 598 cases of  
157 hospitalization among the chronically ill. The VE against confirmed infection 21+ days since the  
158 first vaccination with any vaccine was 51% (95% confidence interval: 44–58%) in the elderly and  
159 48% (41–54%) in the chronically ill. The corresponding VE against hospitalization was 66% (53–  
160 76%) and 69% (55–79%), respectively.

161

162 In both cohorts, the hazards of confirmed infection and hospitalization during the follow-up of less  
163 than 7 days since first vaccination were significantly lower than the corresponding hazards in the  
164 unvaccinated follow-up (Supplementary Tables 4, 5 and 6). This initial difference between the

165 vaccinated and unvaccinated decreased during the first 2–3 weeks. VE estimates against  
166 confirmed infection and hospitalization started to rise 14 and 21 days after vaccination.

167

168 In the elderly, the effectiveness of exactly 1 dose of any mRNA vaccine against confirmed infection  
169 and hospitalization 21+ DSV was 45% (95% confidence interval: 36–53%) and 63% (49–74%)  
170 respectively. After the first three weeks since vaccination, VE against infection was constant, while  
171 VE against hospitalization further increased over time (Table 1). After the second mRNA  
172 vaccination, VE against confirmed infection and hospitalization was 75% (65–82%) and 93% (70–  
173 98%) (Table 1).

174

175 In the chronically ill, the effectiveness of exactly 1 dose of any mRNA vaccine against confirmed  
176 infection and hospitalization 21+ DSV was 40% (95% confidence interval: 26–51%) and 82% (56–  
177 93%), respectively. Although initially constant, VE appeared to decrease after 42 days (Table 2).  
178 However, the confidence intervals are broad and overlapping. After the second mRNA vaccination,  
179 VE against confirmed infection and hospitalization was 77% (65–85%) and 90% (29–99%) (Table 2).

180

181 The effectiveness of exactly 1 dose of AdV vaccine against confirmed infection and hospitalization  
182 21+ DSV was 42% (95% confidence interval: 32–50%) and 62% (42–75%), respectively. The VE  
183 estimates fluctuated over time but did not decrease after 42 days (Table 3). Due to the small  
184 number of vaccinees given 2 doses of AdV vaccine (Figure 1), the effectiveness of the second AdV  
185 vaccination could not be estimated (Table 3).

186

187

## 188 Discussion

189 The present observational, population-based study quantified the interim effectiveness of Covid-  
190 19 vaccines in the elderly and the chronically ill during the first 5 months of the vaccination  
191 campaign in Finland. Three weeks after the first dose, VE was moderate against confirmed SARS-  
192 CoV-2 infection but considerably higher against Covid-19 hospitalization. After the first mRNA  
193 vaccination (BioNTech/Pfizer or Moderna), the VE estimates were constant in the elderly from the  
194 fourth through the seventh week and beyond. However, we were not able to demonstrate  
195 sustained mRNA VE in the chronically ill for all post-vaccination intervals. Nevertheless, the second  
196 mRNA vaccination increased the VE estimates substantially, both in the elderly and the chronically  
197 ill. After the first AdV vaccination (Oxford/AstraZeneca), the observed VE sustained through all  
198 post-vaccination intervals in the study but VE of the second dose could not be estimated.

199

200 Several studies have previously evaluated VE against SARS-CoV-2 infection. An observational,  
201 population-based study from Israel estimated VE among the elderly aged 70+ years at 50 and 95%  
202 3 weeks after the first dose and 1 week after the second dose of the BioNTech/Pfizer vaccine,  
203 respectively [8]. Although similar, these results might, however, not be fully comparable to our  
204 results as all individuals confined to their homes or long-term care facilities were excluded from  
205 the Israeli study but included in ours. In another study from Israel, VE against asymptomatic and  
206 symptomatic infection was 52% and 63%, respectively, in the third week after the first dose [11].  
207 In England, VE against symptomatic infection in elderly aged 70+ years was estimated at 50% in  
208 the fifth week after the first dose from BioNTech/Pfizer and 61% after the first dose from  
209 Oxford/AstraZeneca [12]. In agreement with our findings, the results by Lopez Bernal et al. [12]  
210 thus indicate that VE levels sustain even beyond the first 3 weeks after the first dose.

211

212 Previous studies have also assessed VE against more severe outcomes and, in line with our study,  
213 detected higher protection levels against Covid-19 hospitalization than infection. In the third week  
214 after the first dose from BioNTech/Pfizer, VE against hospitalization was found to be 74% and 76%  
215 in the general Israeli population aged 16+ years [8,11]. In the subsequent weeks VE of the first  
216 BioNTech/Pfizer dose ranged between 77 and 91% according to a Scottish cohort study [13]. When  
217 stratified by age, the VE after 7 weeks was 76% among those aged 65–79 years and 85% among  
218 those aged 80+ years [13]. In addition, VE was estimated at 77% 2 weeks after the first mRNA  
219 vaccination in a population with history of prior all-cause hospitalization in the United States [14].  
220 While the results of those studies are similar, our findings suggest that the VE of only one dose  
221 might be lower. Nevertheless, the present estimates concerning the VE of two doses are  
222 comparable to the previously published figures ranging between 87 and 97% [8,11,14,15].

223

224 Although a direct comparison of the effectiveness estimates for mRNA and AdV vaccines may be  
225 influenced by the different dates the vaccines were introduced in the population (Figure 1), we did  
226 not detect meaningful differences. This finding is in line with other studies that analyzed the  
227 effectiveness of both mRNA and AdV vaccines against SARS-CoV-2 infection [12] and Covid-19  
228 hospitalization [12,13,16].

229

230 Although our VE estimates were roughly similar to those obtained in previous studies [8,11-14],  
231 our estimates appear to be at the lower side of the spectrum. One reason might be that in Finland  
232 vaccinations were given first to the oldest among the elderly and the most immunocompromised  
233 among the chronically ill. High age seems to affect the effectiveness of Covid-19 vaccines less than  
234 expected based on the experience with other vaccines [8,10,11,13]. Nevertheless, VE was found to

235 be lower among the very old, the immunocompromised and residents of long-term care facilities  
236 [10,17] and to vary across different predisposing medical conditions [10,18].

237

238 In Finland, Alpha was the predominant SARS-CoV-2 variant causing 60–70% of all SARS-CoV-2  
239 infections in the capital region and 50% of all SARS-CoV-2 infections in the rest of the country in  
240 March 2021. At the same time, Beta caused only 5% of the infections [19], but local reports  
241 indicate that the incidence of Beta has increased. Recently, there has been a concern that certain  
242 SARS-CoV-2 variants are associated with higher transmissibility [20], mortality [21], antibody  
243 resistance [22] and capability to cause Covid-19 epidemics in a population with high  
244 seroprevalence [23]. It has been shown that Covid-19 vaccines are effective against Alpha  
245 [11,24,25] but their efficacy against Beta seems to be reduced [26]. VE in Finland might, therefore,  
246 be decreased due to the increased incidence of Beta.

247

248 The main strengths of this analysis are the size and representativeness of the 2 cohorts and the  
249 register-based nature of the study. In Finland, the recording of Covid-19 vaccinations into the  
250 patient information system is mandatory, as is the notification of SARS-CoV-2 positive laboratory  
251 findings. These data are then automatically transferred into the national registers. Because  
252 exposure, outcome and covariate data are recorded directly at the source and independently, the  
253 chance of measurement and recall bias has been minimized. By using Cox regression with time in  
254 study as the underlying time scale, we controlled any temporal changes in the hazard of infection  
255 and disease or detection of those. Moreover, it can be assumed that a great proportion of  
256 symptomatic infections have been captured since the threshold for testing was very low and  
257 testing capacities were at no point exhausted. Covid-19 testing has been free of charge and its  
258 importance emphasized through official channels.

259

260 A limitation of this study is the unknown proportion of asymptomatic cases among the confirmed  
261 infections. As VE is greater when measured against a more severe outcome [8], the proportion of  
262 asymptomatic cases strongly influences the VE estimates. The major weakness is, however, the  
263 presence of time-limited selection bias as in [13]. At the day of vaccination, vaccinees were  
264 healthier than average due to the policy to postpone the vaccination of individuals with acute  
265 symptoms suggestive of Covid-19 and those in self-isolation. Consequently, the hazards of  
266 infection and hospitalization in the recently vaccinated were lower than the hazards in the  
267 unvaccinated. In the absence of any bias, these hazards should have been similar in the vaccinated  
268 and unvaccinated as it takes 2–3 weeks for the vaccine-induced immune response to develop. In  
269 addition, residual confounding may be present due to the observational nature of the study.

270

271

## 272 **Conclusions**

273 Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalization. We detected  
274 no difference between mRNA and AdV vaccines. In the elderly and the chronically ill, a single dose  
275 provides moderate protection even beyond the first 3 weeks since vaccination, yet the full series  
276 of 2 doses is superior. Further studies are needed to assess Covid-19 vaccine effectiveness for  
277 different brands, schedules and target groups.

278

279

280 **Acknowledgements**

281 The authors thank Esa Ruokokoski, Jonas Sundman, Oskari Luomala, Teemu Möttönen and Tuomo  
282 Nieminen from the Finnish Institute for Health and Welfare for their assistance in managing the  
283 study data.

284

285

286 **Authors' contributions**

287 UB, TL and AAP conceptualized the study. HS and TOL identified the medical conditions  
288 predisposing to severe Covid-19. UB conducted the statistical analysis. EP and TL reviewed the  
289 literature. UB and EP drafted the manuscript.

290

291

292 **Conflicts of interest**

293 AAP is an investigator in studies for which the Finnish Institute for Health and Welfare has  
294 received research funding from Sanofi Pasteur, GlaxoSmithKline and Pfizer. All other authors  
295 declare no conflict of interest.

296

297

298 **References**

299 [1] European Centre for Disease Prevention and Control. COVID-19 situation update for the  
300 EU/EEA, as of 9 June 2021. Available at: [https://www.ecdc.europa.eu/en/cases-2019-ncov-](https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea)  
301 [eueea](https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea). Accessed 2021 June 10.

- 302 [2] Finnish Institute for Health and Welfare. Situation update on coronavirus. Available at:  
303 [https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/situation-update-on-coronavirus)  
304 [19-latest-updates/situation-update-on-coronavirus](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/situation-update-on-coronavirus). Accessed 2021 May 25.
- 305 [3] European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in  
306 the EU. Available at: [https://www.ema.europa.eu/en/news/ema-recommends-first-covid-](https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu)  
307 [19-vaccine-authorisation-eu](https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu). Accessed 2021 June 10.
- 308 [4] Finnish Institute for Health and Welfare. Vaccination order and at-risk groups for COVID-  
309 19. Available at: [https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/transmission-and-protection-coronavirus/vaccines-and-coronavirus/vaccination-order-and-at-risk-groups-for-covid-19)  
310 [new/coronavirus-covid-19-latest-updates/transmission-and-protection-](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/transmission-and-protection-coronavirus/vaccines-and-coronavirus/vaccination-order-and-at-risk-groups-for-covid-19)  
311 [coronavirus/vaccines-and-coronavirus/vaccination-order-and-at-risk-groups-for-covid-19](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/transmission-and-protection-coronavirus/vaccines-and-coronavirus/vaccination-order-and-at-risk-groups-for-covid-19).  
312 Accessed 2021 June 10.
- 313 [5] GOV.UK. Optimising the COVID-19 vaccination programme for maximum short-term  
314 impact. Available at: [https://www.gov.uk/government/publications/prioritising-the-first-](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact)  
315 [covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact)  
316 [maximum-short-term-impact](https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact). Accessed 2021 June 10.
- 317 [6] European Centre for Disease Prevention and Control. COVID-19 Vaccine Tracker. Available  
318 at: [https://gap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-](https://gap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab)  
319 [tab](https://gap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab). Accessed 2021 June 10.
- 320 [7] European Medicines Agency. COVID-19 vaccines: authorised. Available at:  
321 [https://www.ema.europa.eu/en/human-regulatory/overview/public-health-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised)  
322 [threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised)  
323 [vaccines-authorised](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised). Accessed 2021 June 10.
- 324 [8] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19  
325 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*, 2021; 384:1412–23.

- 326 [9] Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage  
327 in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against  
328 infection (SIREN): a prospective, multicentre, cohort study. *Lancet*, 2021;  
329 397(10286):1725–35.
- 330 [10] Yelin I, Katz R, Herzl E, Berman-Zilberstein T, Ben-Tov A, Kuint J, et al. Associations of the  
331 BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities [Preprint].  
332 May 24, 2021 [cited 2021 June 10]. Available from:  
333 <https://doi.org/10.1101/2021.03.16.21253686>.
- 334 [11] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness  
335 of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases,  
336 hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an  
337 observational study using national surveillance data. *Lancet*, 2021; 397: 1819–29.
- 338 [12] Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of  
339 the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms,  
340 hospital admissions, and mortality in older adults in England: test negative case-control  
341 study. *BMJ*, 2021; 373:n1088.
- 342 [13] Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-  
343 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a  
344 national prospective cohort study. *Lancet*, 2021; 397(10285):1646–57.
- 345 [14] Vahidy FS, Pischel L, Tano ME, Pan AP, Boom ML, Sostman HD, et al. Real World  
346 Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the  
347 United States [Preprint]. April 23, 2021 [cited 2021 June 10]. Available from:  
348 <https://doi.org/10.1101/2021.04.21.21255873>.

- 349 [15] Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness  
350 of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults  
351 Aged  $\geq 65$  Years — United States, January–March 2021. *MMWR Morb Mortal Wkly Rep.*  
352 2021; 70(18):674–9.
- 353 [16] Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Assessing the Effectiveness of  
354 BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in  
355 Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study [Preprint]. March  
356 3, 2021 [cited 2021 June 10]. Available from:  
357 [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3796835](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3796835).
- 358 [17] Moustsen-Helms IR, Emborg H-D, Nielsen J, Nielsen KF, Krause TG, Mølbak K, et al. Vaccine  
359 effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term  
360 care facility residents and healthcare workers – a Danish cohort study [Internet].  
361 *Epidemiology*; 2021 Mar [Preprint cited 2021 Apr 6]. Available from:  
362 <http://medrxiv.org/lookup/doi/10.1101/2021.03.08.21252200>
- 363 [18] Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort  
364 of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive  
365 Medications. *Gastroenterology*, 2021; S0016-5085(21)03066-3.
- 366 [19] Finnish Institute for Health and Welfare. COVID-19-epidemiaan hybridistrategian seuranta.  
367 Available at:  
368 [https://thl.fi/documents/533963/5860112/Erilliskatsaus.+Muuntuneiden+koronavirusten+](https://thl.fi/documents/533963/5860112/Erilliskatsaus.+Muuntuneiden+koronavirusten+seuranta+II+31.3.2021.pdf)  
369 [seuranta+II+31.3.2021.pdf](https://thl.fi/documents/533963/5860112/Erilliskatsaus.+Muuntuneiden+koronavirusten+seuranta+II+31.3.2021.pdf). Accessed 2021 June 10.
- 370 [20] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated  
371 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*, 2021;  
372 372(6538).

- 373 [21] Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP, Diaz-Ordaz  
374 K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.  
375 Nature, 2021; 593:270–4.
- 376 [22] Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, et al. SARS-CoV-2 variants  
377 B.1.351 and P.1 escape from neutralizing antibodies. Cell, 2021; 184(9):2384-2393.e12.
- 378 [23] Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of  
379 COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet, 2021; 397(10273):452–5.
- 380 [24] Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination.  
381 Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N  
382 Engl J Med, 2021.
- 383 [25] Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1  
384 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an  
385 exploratory analysis of a randomised controlled trial. Lancet, 2021; 397(10282):1351–62.
- 386 [26] Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1  
387 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med, 2021; 384:1885–98.  
388

**Table 1:** mRNA vaccine effectiveness in the Finnish elderly aged 70+ years adjusted for age group, sex, presence of medical conditions, residence in Helsinki-Uusimaa hospital district and residence in long-term care.

|                    | Laboratory-confirmed SARS-CoV-2 infection |                              |  | Covid-19 hospitalization |                              |  |
|--------------------|---|------------------------------|--|--------------------------|------------------------------|--|
|                    | Cases, n                                  | Cumulative risk <sup>a</sup> | Vaccine effectiveness <sup>b</sup> , % | Cases, n                 | Cumulative risk <sup>a</sup> | Vaccine effectiveness <sup>b</sup> , % |
| Not vaccinated     | 1526                                      | 295                          | Reference                              | 319                      | 73                           | Reference                              |
| <b>First dose</b>  |   |                              |  |                          |                              |  |
| 21-27 DSV          | 71  | 249                          | 41 (25–54)                             | 14                       | 33                           | 57 (24–75)                             |
| 28-34 DSV          | 59  | 135                          | 47 (30–59)                             | 13                       | 28                           | 59 (26–77)                             |
| 35-41 DSV          | 56  | 233                          | 46 (28–59)                             | 11                       | 57                           | 64 (32–81)                             |
| 42+ DSV            | 197                                       | 104                          | 46 (35–56)                             | 39                       | 12                           | 68 (50–79)                             |
| <b>Second dose</b> |   |                              |  |                          |                              |  |
| 7+ DSV             | 45  | 132                          | 75 (65–82)                             | 2                        | 3                            | 93 (70–98)                             |

<sup>a</sup> Cumulative risk at the end of the study multiplied by 10000; <sup>b</sup> Point estimate and 95% confidence interval; DSV, days since vaccination.

**Table 2:** mRNA vaccine effectiveness in the chronically ill aged 16–69 years adjusted for age group, sex, presence of medical conditions and residence in Helsinki-Uusimaa hospital district.

|                    | Laboratory-confirmed SARS-CoV-2 infection |                              |  | Covid-19 hospitalization |                              |  |
|--------------------|---|------------------------------|--|--------------------------|------------------------------|--|
|                    | Cases, n                                  | Cumulative risk <sup>a</sup> | Vaccine effectiveness <sup>b</sup> , % | Cases, n                 | Cumulative risk <sup>a</sup> | Vaccine effectiveness <sup>b</sup> , % |
| Not vaccinated     | 5280                                      | 859                          | Reference                              | 528                      | 90                           | Reference                              |
| <b>First dose</b>  |   |                              |  |                          |                              |  |
| 21-27 DSV          | 35  | 242                          | 41 (17–58)                             | 1                        | 2                            | 89 (24–99)                             |
| 28-34 DSV          | 20  | 217                          | 58 (34–73)                             | 1                        | 2                            | 86 (-1 to 98)                          |
| 35-41 DSV          | 13  | 294                          | 59 (29–76)                             | 0                        | 0                            | Not estimated                          |
| 42+ DSV            | 43  | 431                          | 14 (-16 to 37)                         | 3                        | 13                           | 59 (-29 to 87)                         |
| <b>Second dose</b> |   |                              |  |                          |                              |  |
| 7+ DSV             | 20  | 181                          | 77 (65–85)                             | 1                        | 32                           | 90 (29–99)                             |

<sup>a</sup> Cumulative risk at the end of the study multiplied by 10000; <sup>b</sup> Point estimate and 95% confidence

interval; DSV, days since vaccination.

**Table 3:** Adenovirus vector vaccine effectiveness in the chronically ill aged 16–69 years adjusted for age group, sex, presence of medical conditions and residence in Helsinki-Uusimaa.

|                    | Laboratory-confirmed SARS-CoV-2 infection |                              |                          | Covid-19 hospitalization |                              |  |
|--------------------|---|------------------------------|--------------------------|--------------------------|------------------------------|--|
|                    | Cases, n                                  | Cumulative risk <sup>a</sup> | Vaccine effectiveness, % | Cases, n                 | Cumulative risk <sup>a</sup> | Vaccine effectiveness <sup>b</sup> , % |
| Not vaccinated     | 5280                                      | 859                          | Reference                | 528                      | 90                           | Reference                              |
| <b>First dose</b>  |   |                              |                          |                          |                              |  |
| 21-27 DSV          | 51  | 238                          | 24 (-1 to 42)            | 4                        | 42                           | 67 (10–88)                             |
| 28-34 DSV          | 29  | 129                          | 48 (25–64)               | 1                        | 3                            | 91 (33–99)                             |
| 35-41 DSV          | 29  | 184                          | 37 (8–56)                | 6                        | 37                           | 36 (-45 to 72)                         |
| 42+ DSV            | 78  | 106                          | 50 (37–61)               | 15                       | 21                           | 58 (26–76)                             |
| <b>Second dose</b> |   |                              |                          |                          |                              |  |
| 7+ DSV             | 0   | 0                            | Not estimated            | 0                        | 0                            | Not estimated                          |

<sup>a</sup> Cumulative risk at the end of the study multiplied by 10000; <sup>b</sup> Point estimate and 95% confidence

interval; DSV, days since vaccination.

**Figure 1:** Number of vaccinations administered in the 2 study cohorts of Finnish elderly aged 70+ years and chronically ill aged 16–69 years by vaccine manufacturer and week of vaccination.

BioNTech/Pfizer (since Dec 27)
  Moderna (since Jan 20)
  Oxford/AstraZeneca (since Feb 10)

